Drug intelligence / Profile preview

HW211026

Development stage: Phase 2
Lead developer: Humanwell Healthcare
Modality: Small Molecules
Administration: Topical

Overview

HW211026 is a chemical drug under development as a topical ointment, primarily for the treatment of actinic keratosis. It is being developed by Wuhan Humanwell Innovative Drug R & D Center. The drug is currently in Phase 1 clinical trials, with studies focused on evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers after single-dose administration. The mechanism of action and molecular target have not been disclosed publicly. Its primary therapeutic areas are neoplasms and skin/musculoskeletal diseases[1][2][3][4].

Beyond the preview

Go deeper on HW211026.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HW211026.

Explore the full profile